Atrial Fibrillation: Flec-SL trial proves efficacy of short-term antiarrhythmic drug treatment


Short-term antiarrhythmic drug treatment after cardioversion is nearly as effective in preventing recurrences of atrial fibrillation as long-term treatment. This is the result of Flec-SL, a controlled clinical trial conducted by the German Competence Network on Atrial Fibrillation (AFNET). The scientific paper has just been published in the Lancet.

ESC press release